![Sample our Area Studies journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5922/TOC-Subject-Sample-2021-Area-Studies.jpg"})
ABSTRACT
Against the backdrop of rapid population aging, we examine the impacts of population aging on pharmaceutical innovation based on the panel data of OECD countries between 1997 and 2018. We show that population aging effectively boosts the quantity and quality of pharmaceutical innovation before the share of older adults approaches 14%, the threshold for the aged society. Once the country enters the aged society, however, population aging is no longer associated with the quantity of pharmaceutical patents, and even significantly depresses the quality of patenting. Moreover, the type of welfare state regimes plays a notable moderating role. High welfare states could effectively amplify the positive effects of aging or attenuate the negative impacts of aging on pharmaceutical innovation. Our results suggest that the dividend of aging in pharmaceutical industry does exist in the early stage of aging, and the government needs to plan ahead to ameliorate the deterioration of innovation in aged and super-aged societies.
JEL CLASSIFICATION:
Disclosure statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Notes
1. The global life expectancy transiently declined to 72.3 years old in 2020 large due to the COVID-19 pandemic.
2. Japan, Italy, Finland, Portugal, Greece, Germany, Latvia, France.
3. Colombia, Costa Rica, Estonia, Lithuania, Luxembourg, Iceland, New Zealand.
4. Patents in pharmaceuticals refer to patents filed in IPC class A61K, excluding A61K8/* (cosmetics).
5. Missing values account for 11.6% of the total rail lines data and they are filled by interpolation.